Vitamin E for Alzheimer’s dementia and mild cognitive impairment
Abstract Background Vitamin E is a dietary compound that functions as an antioxidant scavenging toxic free radicals. Evidence that free radicals may contribute to the pathological processes of cognitive impairment including Alzheimer’s disease has led to interest in the use of vitamin E in the treatment of mild cognitive impairment (MCI) and Alzheimer’s dementia (AD). […]
Cholinesterase inhibitors for mild cognitive impairment
Abstract Background Mild cognitive impairment is hypothesised to represent a pre-clinical stage of dementia but forms a heterogeneous group with variable prognosis. Objectives To assess the safety and efficacy of cholinesterase inhibitors in people with mild cognitive impairment. Search methods Trials were identified from the Cochrane Dementia and Cognitive Improvement Group’s Specialised Register, which is […]
Hyperbaric oxygen therapy for vascular dementia
Abstract Background Hyperbaric oxygen therapy (HBOT) has been used to treat a variety of conditions and has shown possible efficacy for treating vascular dementia (VaD) in experimental and preliminary clinical studies. Objectives To assess the efficacy and safety of HBOT for VaD, used alone or as an adjuvant treatment. Search methods We searched ALOIS: the […]
Omega 3 fatty acid for the prevention of cognitive decline and dementia
Abstract Background Evidence from observational studies suggests that diets high in omega-3 long-chain polyunsaturated fatty acids (PUFA) may protect people from cognitive decline and dementia. The strength of this potential protective effect has recently been tested in randomised controlled trials. Objectives To assess the effects of omega-3 PUFA supplementation for the prevention of dementia and […]
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease
Abstract Background Previous Cochrane reviews have considered the use of cholinesterase inhibitors in both Parkinson’s disease with dementia (PDD) and dementia with Lewy bodies (DLB). The clinical features of DLB and PDD have much in common and are distinguished primarily on the basis of whether or not parkinsonism precedes dementia by more than a year. […]
Functional analysis-based interventions for challenging behaviour in dementia
Abstract Background Functional analysis (FA) for the management of challenging behaviour is a promising behavioural intervention that involves exploring the meaning or purpose of an individual’s behaviour. It extends the ‘ABC’ approach of behavioural analysis, to overcome the restriction of having to derive a single explanatory hypothesis for the person’s behaviour. It is seen as […]
Cognitive stimulation to improve cognitive functioning in people with dementia
Abstract Background Cognitive stimulation is an intervention for people with dementia which offers a range of enjoyable activities providing general stimulation for thinking, concentration and memory usually in a social setting, such as a small group. Its roots can be traced back to Reality Orientation (RO), which was developed in the late 1950s as a […]
Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer’s disease
Abstract Background Alzheimer’s disease (AD) is the most common form of dementia. The incidence of AD rises exponentially with age and its prevalence will increase significantly worldwide in the next few decades. Inflammatory processes have been suspected in the pathogenesis of the disease. Objectives To review the efficacy and side effects of aspirin, steroidal and […]
Naftidrofuryl for dementia
Abstract Background Dementia is a brain disorder characterized by the permanent loss of higher cognitive functions. A number of vasodilatory drug treatments are prescribed for dementia. Naftidrofuryl is one such medicine which is reported to improve clinical symptoms significantly. The efficacy and possible adverse events of naftidrofuryl need to be reviewed systematically and assessed critically […]
18F PET with flutemetamol for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)
Abstract Background 18F-flutemetamol uptake by brain tissue, measured by positron emission tomography (PET), is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer’s pathology in an established dementia diagnosis. However, […]